{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:09:16Z","timestamp":1776942556918,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009845","name":"Ovarian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["1050134"],"award-info":[{"award-number":["1050134"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["1067589"],"award-info":[{"award-number":["1067589"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T14:16:40Z","timestamp":1614089800000},"page":"374-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer"],"prefix":"10.1016","volume":"161","author":[{"given":"Katrin M.","family":"Sjoquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumitra","family":"Ananda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bowtell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.02.002_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncologist."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.002_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/23809000.2016.1185369","article-title":"The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer","volume":"1","author":"Suidan","year":"2016","journal-title":"Expert Rev. Qua. Life Cancer Care"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.002_bb0020","article-title":"Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis","volume":"28","author":"Hilal","year":"2017","journal-title":"J."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.002_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000080457","article-title":"Accumulation of selected carotenoids, alpha -tocopherol and retinol in human ovarian carcinoma Ascitic fluid","volume":"48","author":"Schweigert","year":"2004","journal-title":"Ann. Nutr. Metab."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.002_bb0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1742271X16680653","article-title":"Ascites matters","volume":"25","author":"Rudralingam","year":"2017","journal-title":"Ultrasound."},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.002_bb0035","first-page":"14","article-title":"Biological pathways involved in tumor angiogenesis and bevacizumab based anti-Angiogenic therapy with special references to ovarian Cancer","volume":"18","author":"Loizzi","year":"2017","journal-title":"Int."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.002_bb0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12032-014-0292-1","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2021.02.002_bb0045","doi-asserted-by":"crossref","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastroin. Surg."},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.002_bb0050","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin. Ther."},{"issue":"33","key":"10.1016\/j.ygyno.2021.02.002_bb0055","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian Cancer or peritoneal serous Cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2021.02.002_bb0060","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian Cancer or primary peritoneal Cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2021.02.002_bb0065","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2021.02.002_bb0070","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2021.02.002_bb0075","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2021.02.002_bb0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian Cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.02.002_bb0085","series-title":"Bevacizumab Product Information","author":"Ltd RP","year":"2010"},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.002_bb0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.amjsurg.2009.08.038","article-title":"Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions","volume":"200","author":"Ignjatovic","year":"2010","journal-title":"Am. J. Surg."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.002_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.002_bb0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.02.002_bb0105","series-title":"Peritoneal-plasma Barrier. Peritoneal Carcinomatosis: Principles of Management","first-page":"53","author":"Jacquet","year":"1996"},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.002_bb0110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","article-title":"Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer","volume":"111","author":"Hamilton","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2021.02.002_bb0115","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"El-Shami","year":"2007","journal-title":"J. Clin. Oncol. (Meeting Abstracts)"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.002_bb0120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10637-009-9351-4","article-title":"Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review","volume":"28","author":"Bellati","year":"2010","journal-title":"Investig. New Drugs"},{"issue":"33","key":"10.1016\/j.ygyno.2021.02.002_bb0125","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian Cancer or peritoneal serous Cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.002_bb0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.002_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12032-014-0292-1","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.002_bb0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.ygyno.2021.02.002_bb0145","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.002_bb0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/IGC.0000000000000167","article-title":"Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer","volume":"24","author":"King","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.002_bb0155","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.002_bb0160","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:46:56Z","timestamp":1715820416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090825821001098"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}